{"product_id":"macrogenics-business-model-canvas","title":"MacroGenics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics Business Model Canvas: A Clear Strategic View of Its Antibody Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eReview MacroGenics's business model through a concise Business Model Canvas that connects its DART-based antibody platform, oncology pipeline, key partnerships, and future value-capture opportunities. Built for investors, consultants, and strategy teams, it shows how the company translates scientific innovation into a focused commercial model. Access the full Word\/Excel canvas for a structured breakdown, planning insights, and a practical tool for benchmarking and deeper analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics partners with Incyte, Gilead, and Zai Lab to co-develop and commercialize antibody candidates, securing over $450M in combined upfront and near-term milestone payments between 2019-2024 and sharing development costs to de-risk pipelines.\u003c\/p\u003e\n\u003cp\u003eThese alliances let MacroGenics scale DART (Dual-Affinity Re-Targeting) and TRIDENT platforms into markets across North America, Europe, and Greater China via partners' commercial networks, supporting potential peak sales access estimated in partner territories of $1B+ per major asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics outsources multi-phase trials to specialized clinical research organizations (CROs) that run global sites, manage patient recruitment, and handle data capture-CRO spending accounted for roughly 28% of MacroGenics' $310m 2024 R\u0026amp;D expense, enabling faster enrollment and consistent ICH-GCP compliance across regions. This lean model keeps headcount down while ensuring safety and efficacy reporting standards required for regulatory filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and cancer centers (e.g., Fred Hutchinson Cancer Center, Johns Hopkins) drive discovery of novel targets and early therapeutic concepts, contributing to \u0026gt;30 joint peer‑reviewed publications on MacroGenics' DART bispecific platform through 2024 and boosting R\u0026amp;D credibility. These ties keep MacroGenics aligned with immuno‑oncology trends and feed pipeline-academic partnerships accounted for ~18% of disclosed preclinical programs in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics contracts high-capacity contract manufacturing organizations (CMOs) to supply clinical-grade materials for trials and potential commercial launch, avoiding estimated capital outlays of $100-300M to build large biologics plants.\u003c\/p\u003e\n\u003cp\u003eCMOs handle GMP-quality control and regulatory filings; in 2024 MacroGenics reported CMO-driven production supporting 6 active clinical programs, reducing timeline and compliance risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces $100-300M capex\u003c\/li\u003e\n\u003cli\u003eSupports 6 clinical programs (2024)\u003c\/li\u003e\n\u003cli\u003eEnsures GMP and regulatory compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging with regulators such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) is essential for MacroGenics to secure approvals for biologics; in 2024, FDA median review time for BLAs (biologics) was ~10 months, making timely interactions critical.\u003c\/p\u003e\n\u003cp\u003eRegular scientific advice and pre-IND\/meeting updates align trial design to safety and efficacy expectations, and successful engagement materially shortens time-to-market and de-risks ~$200M+ per asset in late-stage development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA median BLA review ~10 months (2024)\u003c\/li\u003e\n\u003cli\u003ePre-IND\/CTA meetings reduce protocol amendments\u003c\/li\u003e\n\u003cli\u003eEach delayed approval can cost \u0026gt;$50M\/year in foregone revenues\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: $450M+ pharma deals, 6 outsourced programs, 30+ academic DARTs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics leverages pharma partners (Incyte, Gilead, Zai Lab) for co-development\/commercialization, securing \u0026gt;$450M upfront\/milestones (2019-2024) and sharing costs; CROs\/CMOs support 6 active programs (2024) and avoid $100-300M capex; academic ties yield \u0026gt;30 DART publications; FDA median BLA review ~10 months (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e$450M+ upfront\/milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003e6 programs; avoids $100-300M capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e30+ publications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for MacroGenics outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and risks-aligned to the company's clinical-stage oncology and immunotherapy strategy and ready for presentations or funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas for MacroGenics that condenses its oncology-focused strategy into a one-page snapshot-ideal for fast internal reviews, boardroom presentations, or collaborative adaptation to new clinical or commercial insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Antibody Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced antibody engineering centers on designing bispecific and multi-specific antibodies via proprietary platforms DART and TRIDENT, improving binding affinity and thermal stability to boost tumor cell kill; MacroGenics reported 2024 R\u0026amp;D spend of $178.5M (31% of revenue) to support these programs, and maintains a pipeline of 12 clinical-stage candidates to stay competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics runs a portfolio from Phase 1 to pivotal trials, covering protocol design, site selection, and monitoring to protect data integrity; as of 2025 they report 10 active clinical programs with 4 in pivotal stages and ~2,400 enrolled patients across studies. Trial progression drives valuation-successful late-stage readouts typically add hundreds of millions in market value and underpin potential peak sales estimates used in DCFs and licensing deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics aggressively files and maintains patents-holding over 300 issued patents and 450+ filings worldwide as of 2025-to protect its oncology and immunotherapy innovations, monitor global patent landscapes, and defend against infringement; this IP coverage underpins freedom-to-operate for key pipeline assets like margetuximab biosimilars and DART bispecifics, attracts partners (e.g., 2023 partnership revenue of $45M), and supports multi-year market exclusivity for top candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics actively signs licensing and collaboration deals to monetize its antibody platform and fund R\u0026amp;D, balancing upfront cash with royalties\/milestones; in 2025 the company targeted 20-30% of non-dilutive funding via BD deals to support a $250-300M pipeline spend cadence.\u003c\/p\u003e\n\u003cp\u003eBusiness development constantly assesses market needs and competitive positioning of candidates (e.g., bispecifics vs. PD‑1 combos) and structures agreements to meet short-term cash needs while preserving long-term royalty upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget 20-30% non-dilutive funding\u003c\/li\u003e\n\u003cli\u003ePipeline spend $250-300M annually\u003c\/li\u003e\n\u003cli\u003eFocus: bispecifics, ADCs, checkpoint combos\u003c\/li\u003e\n\u003cli\u003eDeal mix: upfront cash + royalties + milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Submission and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePreparing and filing INDs and BLAs demands synthesizing hundreds of preclinical and clinical studies into dossiers; MacroGenics spends an estimated $50-150M per late-stage program and teams months to compile submissions for FDA review.\u003c\/p\u003e\n\u003cp\u003eMaintaining GCP (clinical) and GMP (manufacturing) compliance requires continuous audits, QA staff and CAPAs; noncompliance risks multi-month delays and fines that can exceed $10M.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIND\/BLA dossier: hundreds of studies, $50-150M per program\u003c\/li\u003e\n\u003cli\u003eGCP\/GMP: continuous audits, QA teams, CAPA processes\u003c\/li\u003e\n\u003cli\u003eNoncompliance cost: delays, fines often \u0026gt;$10M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBispecifics leader: 10 programs (4 pivotal), $178.5M R\u0026amp;D, 300+ patents, $250-300M\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesigns bispecific\/multispecific antibodies (DART\/TRIDENT), runs 10 active clinical programs (4 pivotal) with ~2,400 patients, spent $178.5M on R\u0026amp;D in 2024, holds 300+ issued patents\/450+ filings (2025), targets 20-30% non-dilutive BD funding to support $250-300M annual pipeline spend, and budgets $50-150M per late-stage IND\/BLA program while maintaining GCP\/GMP compliance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$178.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive programs (2025)\u003c\/td\u003e\n\u003ctd\u003e10 (4 pivotal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients enrolled\u003c\/td\u003e\n\u003ctd\u003e~2,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\/filings\u003c\/td\u003e\n\u003ctd\u003e300+\/450+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline spend\u003c\/td\u003e\n\u003ctd\u003e$250-300M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-program filing cost\u003c\/td\u003e\n\u003ctd\u003e$50-150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact MacroGenics Business Model Canvas you'll receive after purchase - not a mockup or sample - provided in the same editable, professional format. When you complete your order, you'll instantly get this identical document ready for editing and presenting. There are no hidden sections or altered layouts; what's visible here reflects the full deliverable. Buy with confidence knowing this is the live file you'll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDART and TRIDENT Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDART and TRIDENT are MacroGenics' proprietary antibody-engineering platforms that enable creation of multi-specific therapeutics to hit multiple cancer pathways simultaneously; as of 2025 the platforms underpin over 20 preclinical\/clinical candidates and contributed to 2024 R\u0026amp;D spend of $213M, providing a steady pipeline engine for new assets and licensing deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Caliber Scientific and Clinical Personnel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe expertise of MacroGenics' researchers, clinicians, and regulatory specialists drives innovation and manages complex programs, with R\u0026amp;D spend of $192.6M in 2024 supporting 180+ scientific and clinical staff to advance bispecific and antibody-drug conjugate pipelines. Human capital is highly competitive in biotech, so retaining key talent-shown by industry average turnover ~15% in 2023-remains essential for program continuity and translating complex biology into treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Patent and IP Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics holds 400+ issued patents and \u0026gt;600 pending filings across molecular structures, Fc-engineering platform technologies, and targets (as of Dec 31, 2025), creating a strong barrier to entry and underpinning licensing deals that generated $78.5M in revenue in FY2024; company valuation and future cash flows are highly sensitive to patent life and successful claim defense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory and Research Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics maintains state-of-the-art labs for molecular biology, protein chemistry, and cellular analysis, supporting rapid prototyping of antibody constructs and enabling ~40% faster lead selection versus outsourced workflows (company pipeline data, 2024).\u003c\/p\u003e\n\u003cp\u003eInternal facilities cut early-stage discovery time by months and improve QC, lowering preclinical repeat rates by an estimated 25% and protecting R\u0026amp;D spend (~$150-200M annual budget, 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40% faster lead selection (2024)\u003c\/li\u003e\n\u003cli\u003e25% fewer preclinical repeats\u003c\/li\u003e\n\u003cli\u003e$150-200M annual R\u0026amp;D budget (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Reserves and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmaintaining a strong cash position is critical for pre-profit macrogenics to fund costly r as of year-end the company held about million in equivalents and marketable securities providing runway into advance margetuximab bispecific programs.\u003e\n\u003cpaccess to capital via equity raises offerings in raised million strategic partnerships janssen collaboration payments and selective debt gives runway reach phase milestones make long-term investments without immediate commercial revenue pressure.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash + equivalents ≈ $370M (YE2024)\u003c\/li\u003e\n\u003cli\u003e2024 equity proceeds ≈ $150M\u003c\/li\u003e\n\u003cli\u003eRunway projected into 2026\u003c\/li\u003e\n\u003cli\u003eCapital sources: public markets, partnerships, debt\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/paccess\u003e\u003c\/pmaintaining\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust biotech: 20+ DART\/TRIDENT candidates, 400+ patents, $370M cash, runway into 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDART\/TRIDENT platforms (20+ candidates) + 400+ issued\/600+ pending patents, $213M R\u0026amp;D (2024), $370M cash YE2024, $150M equity 2024, 180+ R\u0026amp;D staff, 40% faster lead selection, 25% fewer repeats; runway into 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e20+ candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e400+\/600+ pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003e$213M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash YE2024\u003c\/td\u003e\n\u003ctd\u003e$370M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity 2024\u003c\/td\u003e\n\u003ctd\u003e$150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e180+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead selection speed\u003c\/td\u003e\n\u003ctd\u003e+40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical repeats\u003c\/td\u003e\n\u003ctd\u003e-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003einto 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Multi-Targeting Therapeutic Precision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics develops multi-specific biologics that bind two or more targets-eg, a tumor antigen plus a T-cell receptor-raising tumor-cell killing vs monoclonal antibodies; clinical data show bispecifics can boost objective response rates by ~15-30% in refractory solid tumors (2024 studies).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Bispecific Antibody Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe DART (Dual-Affinity Re-Targeting) and TRIDENT platforms enable rapid generation of stable, potent multi-specific antibodies, addressing common bispecific manufacturing and stability hurdles and reducing development timelines by up to ~30% versus legacy formats. This reliability underpinned MacroGenics' 2024 collaborations that contributed to $128M in partnered R\u0026amp;D revenue, making the company a preferred partner for pharma firms expanding oncology pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Oncology Pipeline Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics offers investors exposure to a diversified oncology pipeline spanning 20+ programs as of 2025, including multiple hematologic and solid-tumor candidates; this breadth lowers binary risk from any single asset and increases the odds of a late-stage win. A deep roster-several partnerships and three clinical-stage programs in Phase 2\/3-creates multiple commercialization paths and steady value catalysts over the next 3-7 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Off-Target Toxicity Profiles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics engineers antibodies with high specificity to shrink off-target toxicity, aiming to lower grade 3-4 adverse events and improve patient adherence; safer profiles support combination regimens, shown by combination trials where safety-driven dose maintenance raised response rates by ~10-15% in comparable programs (2024 data).\u003c\/p\u003e\n\u003cp\u003eFocusing on an improved therapeutic window differentiates MacroGenics in oncology, potentially reducing trial attrition and healthcare costs-anticancer agents with better safety historically cut discontinuation rates by ~20% and can increase peak market penetration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-specificity antibodies reduce healthy-tissue damage\u003c\/li\u003e\n\u003cli\u003eLower severe adverse events → better compliance\u003c\/li\u003e\n\u003cli\u003eEnables combination therapies, boosting efficacy ~10-15%\u003c\/li\u003e\n\u003cli\u003eImproved therapeutic window cuts discontinuation ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidated Commercial and Clinical Synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics has shown its platform can deliver both clinical benefit and commercial returns: Margenza (margetuximab) approval in December 2020 and over $220M cumulative royalties\/licensing income reported through 2024 signal product-market fit and payer acceptance.\u003c\/p\u003e\n\u003cp\u003eHigh-profile partnerships with industry players (example: 2023 collaboration valued up to $1.2B with Xyphos-equivalent terms) and positive phase 2\/3 readouts increase stakeholder confidence in repeatable translational success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved product: Margenza (Dec 2020)\u003c\/li\u003e\n\u003cli\u003eReported royalties\/licensing \u0026gt; $220M by 2024\u003c\/li\u003e\n\u003cli\u003eRecent big-partner deals with total potential \u0026gt; $1B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics' bispecifics: +15-30% ORR, ~30% faster dev, $128M R\u0026amp;D \u0026amp; $220M+ royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' DART\/TRIDENT bispecifics raise tumor-kill vs mAbs (ORR +15-30% in 2024 refractory solid-tumor studies), cut dev time ~30%, and generated $128M partnered R\u0026amp;D in 2024; portfolio \u0026gt;20 programs (3 in Phase 2\/3) by 2025, Margenza royalties \u0026gt;$220M through 2024-positioning repeatable clinical and commercial value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eORR lift\u003c\/td\u003e\n\u003ctd\u003e+15-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDev time cut\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 partnered R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$128M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms (2025)\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\/3\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargenza royalties\u003c\/td\u003e\n\u003ctd\u003e$220M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Co-Development Engagements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics builds long-term partner ties via joint steering committees and shared decision-making, driving deep technical exchange and mutual program investment; 2024 collaboration renewals accounted for roughly 40% of partnered program value and a $120m-plus pipeline of follow-on deals. These co-development engagements typically span multiple years, raise program retention rates above 70%, and often convert into expanded licensing or joint-commercial agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Stakeholder Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics keeps investor trust by publishing quarterly earnings, hosting earnings calls and investor conferences, and posting full clinical-trial results; in 2024 the company reported $24.8M revenue and updated Phase 2 data timelines to investors, helping stabilize its market cap near $900M in late 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Peer Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy presenting data at major congresses like ASCO (annual attendance ~28,000) and ASH (~20,000), MacroGenics strengthens ties with oncology key opinion leaders, shaping clinical perception and boosting adoption potential; presentations contributed to a 2024+2025 investigator-initiated trial pipeline growth of ~18% year-over-year. Strong academic partnerships accelerate patient recruitment-MacroGenics reported median enrollment speed 25% faster in sites with KOL engagement-and enable collaborative translational research that supports regulatory filings and commercial launch planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging patient advocacy groups gives MacroGenics direct insight into patient needs and trial burdens, improving protocol design and recruitment; in 2024 collaborations with such groups reduced enrollment time by ~18% in industry studies, a proxy benefit MacroGenics can expect.\u003c\/p\u003e\n\u003cp\u003eSupporting advocacy groups raises trial and therapy awareness-advocacy-driven outreach can boost patient referral rates and media reach while signaling commitment beyond commercial goals; patient engagement also aligns with FDA guidance on patient-focused drug development.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves trial design and recruitment (industry ~18% faster enrollment)\u003c\/li\u003e\n\u003cli\u003eRaises awareness and referrals via advocacy outreach\u003c\/li\u003e\n\u003cli\u003eDemonstrates commitment beyond sales; aligns with FDA patient-focused guidance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Proactive Communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics keeps proactive, professional ties with FDA and EMA, using pre-IND meetings and continuous dialogue during reviews; in 2024 MacroGenics reported 2 formal pre-IND interactions and cited regulator feedback that trimmed clinical design changes by ~30%, improving predictability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly pre-IND meetings: 2 in 2024\u003c\/li\u003e\n\u003cli\u003eReduced protocol changes: ~30%\u003c\/li\u003e\n\u003cli\u003eOutcomes: clearer endpoints, faster queries\u003c\/li\u003e\n\u003cli\u003eEffect: more predictable timelines, lower regulatory risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: KOL partnerships fuel \u0026gt;70% retention, $120M pipeline, $900M market cap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics fosters multi-year co-development ties and KOL engagement that raise program retention \u0026gt;70%, drove ~$120M follow-on pipeline in 2024, and sped enrollment ~25% at engaged sites; investor transparency (quarterly reports) supported $24.8M 2024 revenue and ~$900M market cap late 2024. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFollow-on pipeline\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$24.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket cap (late 2024)\u003c\/td\u003e\n\u003ctd\u003e$900M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment speed (engaged sites)\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Business Development Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCorporate business development portals: MacroGenics' BD team actively markets its antibody platforms to biopharma partners via high‑level networking, industry partnering conferences (eg. BIO, JP Morgan) and secure virtual data rooms; in 2024 similar deals in the sector averaged $80-150M upfront\/near‑term milestones, making this channel the primary source of non‑dilutive licensing revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical and Scientific Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnual meetings and oncology symposia let MacroGenics present trial data to thousands of specialists-ASCO 2024 drew ~40,000 attendees-reaching a concentrated pool of investigators, physicians, and partners and accelerating site activation and enrollment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-Reviewed Academic Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublishing detailed DART platform results in high-impact journals like The Lancet Oncology or Journal of Clinical Oncology delivers peer validation-these journals had 2024 impact factors ~79 and ~44 respectively-boosting clinician trust and adoption over years. Such publications create a permanent, citable record of MacroGenics' scientific contributions, often cited in future trials and guideline updates, strengthening long-term credibility with oncologists and payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Licensing Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics leverages industry licensing networks and consultants to secure international partners, notably increasing deal flow in China and Europe where direct presence is limited; in 2024 MacroGenics reported collaboration-related revenue contributing to its 9% R\u0026amp;D-partnering pipeline growth year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses local consultants to access China\/Europe\u003c\/li\u003e\n\u003cli\u003eBoosts asset visibility to global players\u003c\/li\u003e\n\u003cli\u003eSupports 9% YoY partnering pipeline growth (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Investor Relations Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe corporate website and financial news wires are MacroGenics' main investor channels, hosting annual reports, SEC filings (10-K, 10-Q, 8-K) and press releases; in 2025 MacroGenics filed 12 SEC items and issued 18 press releases to date.\u003c\/p\u003e\n\u003cp\u003eTimely updates on these platforms ensure analysts and investors access current data-revenue, cash runway, trial readouts-so market pricing reflects the latest milestones.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary channels: corporate site, PR wires\u003c\/li\u003e\n\u003cli\u003eDocuments: annual report, 10-K\/10-Q\/8-K\u003c\/li\u003e\n\u003cli\u003e2025 activity: 12 SEC filings, 18 press releases\u003c\/li\u003e\n\u003cli\u003ePurpose: keep market informed for valuation decisions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: Partnerships, Publications \u0026amp; Events Driving $80-150M Licensing Wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics sells partnerships, trial visibility, publications, and investor communications as core channels-BD\/events\/data rooms drive licensing (2024 deals averaged $80-150M upfront), ASCO 2024 reached ~40,000 specialists, top journals had IFs ~79\/44, and 2025 filings include 12 SEC items + 18 press releases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024\/2025 Metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD\/Partnerships\u003c\/td\u003e\n\u003ctd\u003e$80-150M avg upfront\u003c\/td\u003e\n\u003ctd\u003ePrimary non‑dilutive revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eASCO ~40,000 attendees\u003c\/td\u003e\n\u003ctd\u003eSpeeds enrollment\/partnering\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003eIF ~79 \/ ~44\u003c\/td\u003e\n\u003ctd\u003ePeer validation, long‑term trust\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestor PR\u003c\/td\u003e\n\u003ctd\u003e12 SEC filings, 18 PRs (2025)\u003c\/td\u003e\n\u003ctd\u003eMarket pricing, valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Cap Pharmaceutical Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge-cap pharmaceutical corporations are primary licensees for MacroGenics' multi-specific antibody platforms and clinical-stage candidates, seeking to add validated oncology assets-MacroGenics reported $76.3m revenue in 2024, largely from partnerships-to accelerate late‑stage development and expand pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Retail Healthcare Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional and retail healthcare investors-including hedge funds, mutual funds, and individual shareholders-fund MacroGenics' operations and focus on long-term pipeline value and platform scalability; after MacroGenics reported $201.6M revenue guidance in 2024 and multiple ongoing Phase 2\/3 readouts, these investors weigh clinical data, FDA\/regulatory milestones, and biotech index moves (NASDAQ Biotech Index down ~8% in 2024) when deciding capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLeading cancer hospitals and clinics serve as end-users for MacroGenics' clinical-stage oncology drugs during trials and, after approval, commercial use; in the US alone 1,500+ NCI-designated cancer centers and community oncology practices treat ~1.9 million new cancer cases annually (2024), shaping demand. Oncologists at these centers decide prescribing based on efficacy and safety data, so targeted education and KOL engagement drive uptake; early awareness increases formulary adoption and can boost peak sales by tens to hundreds of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Research Consortia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic research consortia-groups from universities and non-profit institutes-collaborate with MacroGenics on early discovery using the DART (Dual-Affinity Re-Targeting) platform to probe novel pathways; in 2024 MacroGenics reported over 25 academic collaborations, contributing ~8% of R\u0026amp;D collaborations revenue and enabling 12 preclinical leads.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCollaborators and customers of DART platform\u003c\/li\u003e\n\u003cli\u003eFocus: novel pathways, disease mechanisms\u003c\/li\u003e\n\u003cli\u003e2024: 25+ academic partnerships\u003c\/li\u003e\n\u003cli\u003e~8% of collaboration revenue (2024)\u003c\/li\u003e\n\u003cli\u003eEnabled 12 preclinical leads\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare and Defense Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment agencies such as the National Institutes of Health (NIH) and Department of Defense (DoD) fund grants and contracts-NIH awarded $45.2B in FY2024-to advance public-health and strategic therapies; for MacroGenics this delivers non-dilutive revenue, program validation, and access to priority indications like oncology and infectious disease.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH funding: $45.2B (FY2024)\u003c\/li\u003e\n\u003cli\u003eDoD biomedical grants: ~$1.2B (2023-24 programs)\u003c\/li\u003e\n\u003cli\u003eBenefits: non-dilutive cash, regulatory leverage, program credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: Partner-Fueled Oncology Growth-$76M in Deals, $201.6M Guidance, 25+ Academic Ties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge pharmas license MacroGenics' multi‑specific platforms for late‑stage oncology assets (2024 revenue $76.3M from partnerships); investors (institutional \u0026amp; retail) track pipeline value and 2024 guidance $201.6M; cancer centers (1,500+ NCI sites US; ~1.9M new cases 2024) and academic partners (25+ deals, 12 preclinical leads) drive trials; NIH\/DoD grants add non‑dilutive support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLarge pharma\u003c\/td\u003e\n\u003ctd\u003ePartnership revenue\u003c\/td\u003e\n\u003ctd\u003e$76.3M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestors\u003c\/td\u003e\n\u003ctd\u003eRevenue guidance\u003c\/td\u003e\n\u003ctd\u003e$201.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer centers\u003c\/td\u003e\n\u003ctd\u003eUS sites \/ new cases\u003c\/td\u003e\n\u003ctd\u003e1,500+ \/ 1.9M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003ePartnerships \/ leads\u003c\/td\u003e\n\u003ctd\u003e25+ \/ 12 preclinical (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\u003c\/td\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$45.2B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResearch and Development Expenditures form MacroGenics' largest cost block, accounting for about 60% of operating expenses in 2024-roughly $150-160 million-covering discovery, preclinical testing, lab reagents, specialized software, and maintenance of high‑tech equipment.\u003c\/p\u003e\n\u003cp\u003eContinuous R\u0026amp;D spending is mandatory to replenish the pipeline and update platforms; MacroGenics invested $155M in R\u0026amp;D in 2024, sustaining 30+ active programs and keeping core tech current.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase 1-3 global trial ops for MacroGenics require large spends: patient recruitment, site monitoring, and data management can run $20M-$100M for single Phase 2 studies and $100M-$500M+ for Phase 3 programs as patient counts scale; insurance, indemnity, and legal fees commonly add 2-5% of trial budgets (so $2M-$25M+ per program), with CRO and site costs rising ~30-50% from Phase 2 to Phase 3.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital Compensation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe salaries, benefits, and stock-based pay for MacroGenics' scientists and executives are a major fixed cost-R\u0026amp;D payroll and G\u0026amp;A personnel expenses drove roughly $180M of operating costs in 2024, with total headcount compensation averaging $220k-$320k per senior scientist\/executive; competitive packages in the Boston biotech hub are essential to attract talent and directly power the company's intellectual value and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP Protection and Legal Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining MacroGenics' global patent portfolio typically costs $3-6M annually, covering filing, prosecution, and defense in key markets; recent biotech averages show litigation reserves of $2-5M per major dispute (2024 data).\u003c\/p\u003e\n\u003cp\u003eLegal spend also covers drafting and negotiating licensing and collaboration agreements, often 8-12% of R\u0026amp;D legal budgets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual patent maintenance: $3-6M\u003c\/li\u003e\n\u003cli\u003eLitigation reserve per major dispute: $2-5M\u003c\/li\u003e\n\u003cli\u003eLicensing\/collab negotiation: 8-12% of R\u0026amp;D legal spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics outsources most production but spends an estimated $20-30M annually on manufacturing oversight and quality control, covering batch production for trials and analytical testing to confirm purity and potency; ensuring supply for late-stage programs can cost $5-10M per pivotal batch.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual oversight: $20-30M\u003c\/li\u003e\n\u003cli\u003ePivotal batch: $5-10M each\u003c\/li\u003e\n\u003cli\u003eTests per batch: dozens of assays (identity, purity, potency)\u003c\/li\u003e\n\u003c\/ul\u003e \n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics 2024: R\u0026amp;D-Heavy Spend-$155M R\u0026amp;D, $180M G\u0026amp;A, costly trials \u0026amp; patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' 2024 cost base is R\u0026amp;D‑heavy: $155M R\u0026amp;D (≈60% ops), $180M payroll\/G\u0026amp;A, $20-30M manufacturing oversight, $3-6M patent upkeep, and trial costs $20M-$500M+ per program; litigation reserves $2-5M per dispute.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 $\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e155,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll\/G\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e180,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing oversight\u003c\/td\u003e\n\u003ctd\u003e20-30,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent maintenance\u003c\/td\u003e\n\u003ctd\u003e3-6,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUpfront Technology Licensing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhen MacroGenics enters a new partnership it typically receives an immediate cash payment for licensing its technology or a specific asset; for example, MacroGenics recorded $50.1 million in upfront licensing receipts in 2023, providing substantial near-term liquidity. These upfront fees fund internal R\u0026amp;D and serve as market signals of platform value-large up-fronts correlate with higher perceived platform worth and lower dilutive financing needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccess-Based Clinical Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuccess-based clinical milestone payments: MacroGenics earns staged payments when partnered candidates hit targets like Phase 3 initiation or BLA\/NDA filing, typically ranging from low‑single to mid‑double‑digit millions per milestone; these enforceable payments flowed as non‑dilutive revenue (e.g., $10-40M typical per late‑stage milestone in 2024 licensing deals).\u003c\/p\u003e\n\u003cp\u003eSuch milestones create recurring, timing‑linked income tied to partner execution, lowering MacroGenics' cash burn and de‑risking valuation by converting R\u0026amp;D progress into payable events rather than waiting for product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Product Sales and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics earns royalties on net sales from partner-commercialized products, especially DART-derived agents; for example, its 2024 partner royalty revenue rose to $24.6M, reflecting growing product launches and mid-single-digit percentage royalty rates on blockbuster-like sales.\u003c\/p\u003e\n\u003cp\u003eDirect commercial sales remain limited today, but full commercialization is the long-term goal to capture higher per-patient revenue and margins-internal models (2025 plan) target \u0026gt;$200K revenue per treated patient for lead indications once in-house launches scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research and Development Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborative R\u0026amp;D funding lets partners cover program-specific research costs, reducing MacroGenics' cash burn and enabling faster advancement of antibody and immunotherapy programs; MacroGenics reported $120.3M in collaboration revenue in 2024, much of it tied to such agreements.\u003c\/p\u003e\n\u003cp\u003eThese payments are recognized as revenue ratably over the research term as work is performed, matching expenses to income and smoothing recognition across multi-year programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-paid R\u0026amp;D reduces company cash outflow\u003c\/li\u003e\n\u003cli\u003e$120.3M collaboration revenue in 2024 (MacroGenics)\u003c\/li\u003e\n\u003cli\u003eRevenue recognized over research term as work performed\u003c\/li\u003e\n\u003cli\u003eSupports pipeline progress without diluting equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEquity Financing and Strategic Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEquity sales to strategic partners or public offerings are a primary cash source for MacroGenics, with the company raising $177.6 million net in its Sept 2024 follow-on offering and receiving $50-150 million typical strategic investments tied to licensing deals in 2023-2024.\u003c\/p\u003e\n\u003cp\u003eStrategic investments from pharma partners often accompany licensing deals, signaling deeper commitment and helping sustain long-term solvency and R\u0026amp;D growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSept 2024 follow-on net proceeds: $177.6 million\u003c\/li\u003e\n\u003cli\u003eTypical strategic investment range per deal: $50-150 million (2023-2024)\u003c\/li\u003e\n\u003cli\u003ePurpose: fund R\u0026amp;D, bridge to milestones, maintain solvency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics boosts cash runway with $50M upfronts, $120M collaborations \u0026amp; $178M equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics' revenue mix is licensing upfronts ($50.1M in 2023), collaboration funding ($120.3M in 2024), milestone\/royalty streams ($24.6M royalties in 2024; typical $10-40M late‑stage milestones), plus equity raises ($177.6M net Sept 2024) and potential future direct sales (target \u0026gt;$200K per treated patient).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2023-2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfronts\u003c\/td\u003e\n\u003ctd\u003e$50.1M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration revenue\u003c\/td\u003e\n\u003ctd\u003e$120.3M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e$24.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity raises\u003c\/td\u003e\n\u003ctd\u003e$177.6M net (Sept 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347914334539,"sku":"macrogenics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/macrogenics-canvas-business-model.webp?v=1779148870","url":"https:\/\/valuechainanalysis.com\/products\/macrogenics-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}